Current Vacancies in myaware...click here for more details. Read more
500,000 people have been forgotten and left behind, unfairly affected by Covid. Many are still shielding, still in isolation. Still unable to work, see friends or hug loved ones. Evusheld offers them the chance to live a more normal and free life. Read more
Join myaware, amend your membership, or cancel Read more
Ways to support myaware while you are at home Read more
COUCH Health is inviting people living in the UK with myasthenia gravis to participate in an online interview session. Read more
Myaware and MDUK sent a joint letter to NICE and the related companies about targeted therapeutics in the myasthenia community. Read more about our letter and petition here Read more
A webinar recording by Dr Katherine Dodd, Neurology Clinical Research Fellow, discussing emerging treatments, exercise, lifestyle, and individualising care using biomarkers on 21st February 2024 Read more
A team at King’s College London has developed a new online peer support platform in collaboration with people living with long-term physical health conditions. They are interested in finding out what people think about the new intervention, such as what they like and dislike. Want to get involved? Read more
Myaware are continuing to engage with the relevant companies linked to the Propantheline Bromide shortage. In the meantime, we have some guidance regarding alternatives and importers for unlicensed propantheline. Read more
Efgartigimod is due to be assessed in a 3rd committee meeting with NICE in May. We are looking for the myaware community to put forth their own comments about the appraisal process so far and have prepared a guide for those who may not have done this before. Read more
There is currently a supply shortage of Propantheline Bromide. Though muscle relaxants can be contraindicated in myasthenia, Buscopan is an alternative. Read more
Applications are now open for funding towards myasthenia specialist nurses Read more
Run for myaware in the AJ Bell Great North Run! Read more
Our Research and Partnerships Officer Charlotte Campbell attended the RDCN meeting in Berlin between November 29th and December 1st 2023. This meeting brought together myasthenia gravis (MG) patient groups across Europe and America with specialist healthcare professionals to discuss how best MG can be treated going forward. Read more
The appraisal for assessment of the use of Ravulizumab on the NHS has been withdrawn by the company. A third committee meeting to assess Efgartigimod has been scheduled for May 2024 following the release of further draft guidance. Myaware are looking for members to get involved and share their views with NICE to emphasise the importance of new treatments to the myasthenia community. Read more
In 2021, Iain M. Carey from St George’s published a study looking into the prevalence of neuromuscular disease in the UK. Read more
Myasthenia is a rare disease and insight from a specialist can help with treatment. Find out if there is a clinician with an interest in myasthenia near you. Read more
New treatments for myasthenia are in development. Find out more about how you can get involved. Read more
Online support groups for people living with myasthenia. Read more
Current myaware research projects, apply for grants and more! Read more
Help raise awareness, get recent news updates...find out more on our awareness page. Read more
Myaware's support services - find out more about how we help people with myasthenia. Read more
Help support myaware through our shop. Read more
Take part in a usability study and help improve autoinjectors used in the treatment of Myasthenia Gravis Read more
Myaware is dedicated to the care and support of people affected by myasthenia. Read more
As of October 2023, NICE have released initial guidance not recommending the use of Ravulizumab on the NHS. Click here to find out more about what this draft guidance entails and how myaware members can provide their input. Read more
This is your chance to win a brand new 73 reg Toyota Aygo X while helping others in the myasthenia community. Read more